上海凯宝(300039) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 343,817,802.76, representing a 1.15% increase compared to CNY 339,907,427.57 in the same period last year[4] - Net profit attributable to shareholders was CNY 57,636,350.93, a 0.70% increase from CNY 57,237,236.12 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 343,817,802.76, a slight increase from CNY 339,907,427.57 in Q1 2021[29] - Net profit for Q1 2022 was CNY 57,142,663.02, showing a marginal decrease from CNY 57,237,236.12 in Q1 2021[32] - Total comprehensive income attributable to the parent company's owners was ¥165,979,475.93, compared to ¥57,237,236.12 in the previous period, indicating significant growth[35] Cash Flow - The net cash flow from operating activities increased by 514.45%, reaching CNY 87,056,121.17, compared to a negative cash flow of CNY -21,005,200.21 in the previous year[4] - Cash inflow from operating activities totaled ¥427,893,178.34, up from ¥325,874,682.61 year-over-year[39] - Cash outflow for operating activities was ¥340,837,057.17, slightly decreased from ¥346,879,882.82 in the previous period[39] - The company reported a net increase in cash and cash equivalents of ¥12,081,417.09, contrasting with a decrease of -¥33,917,259.71 in the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,622,340,110.74, up 7.94% from CNY 3,355,816,769.77 at the end of the previous year[4] - The company's total current assets increased to approximately 2.39 billion yuan, up from 2.25 billion yuan at the beginning of the year, reflecting a growth of about 5.5%[22] - Total liabilities rose to CNY 411,942,503.59, up from CNY 310,904,950.64 in the previous year[28] - The company's total liabilities increased, with accounts payable rising by 58.59% due to increased material costs[9] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,262, with the largest shareholder, Mu Jingwei, holding 16.06% of shares, equating to 168,029,270 shares[14] - The total number of restricted shares at the end of the reporting period is 129,441,631, with no new restrictions added during the period[18] Research and Development - Research and development expenses decreased by 40.86% compared to the previous year, reflecting a focus on project-based investment[10] - Research and development expenses for Q1 2022 were CNY 10,017,656.02, down from CNY 16,939,440.85 in Q1 2021[29] Investment Activities - The company reported a 63.01% decrease in investment income compared to the previous year, primarily due to reduced returns from bank wealth management products[10] - The company’s subsidiary, Shanghai Kaibao Equity Investment Co., Ltd., increased its investment in Chongqing Jize Biotechnology Co., Ltd. to hold 33% of its registered capital, focusing on the development of new food raw materials[19] - Total cash inflow from investment activities was ¥686,319,148.60, an increase from ¥558,424,293.00 year-over-year[39] Other Financial Metrics - The company's weighted average return on equity increased to 5.31%, up 3.11 percentage points from 2.20% in the same period last year[4] - The company received government subsidies amounting to CNY 1,535,647.80 during the reporting period[5] - The company reported a tax expense of CNY 11,338,642.90 for Q1 2022, compared to CNY 10,860,538.69 in the same period last year[32] - Other comprehensive income after tax for Q1 2022 was CNY 108,343,125.00, all attributable to the parent company's shareholders[32]